Takeda Pharmaceutical Co (Takeda Pharmaceutical Co) Long-Term Capital Lease Obligation : $0 Mil (As of Dec. 2023)

View and export this data going back to 2010. Start your Free Trial

What is Takeda Pharmaceutical Co Long-Term Capital Lease Obligation?

Takeda Pharmaceutical Co's Long-Term Capital Lease Obligation for the quarter that ended in Dec. 2023 was $0 Mil.

Takeda Pharmaceutical Co Long-Term Capital Lease Obligation Historical Data

The historical data trend for Takeda Pharmaceutical Co's Long-Term Capital Lease Obligation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Takeda Pharmaceutical Co Long-Term Capital Lease Obligation Chart

Takeda Pharmaceutical Co Annual Data

Trend

Mar14

Mar15

Mar16

Mar17

Mar18

Mar19

Mar20

Mar21

Mar22

Mar23

Long-Term Capital Lease Obligation

Get a 7-Day Free Trial

Takeda Pharmaceutical Co Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Long-Term Capital Lease Obligation	Get a 7-Day Free Trial															-	-	-	-	-

Takeda Pharmaceutical Co (NYSE:TAK) Long-Term Capital Lease Obligation Explanation

Long-Term Capital Lease Obligation are the amount due for long-term asset lease agreements that are nearly equivalent to asset purchases. Capital lease obligations are installment payments that constitute a payment of principal plus interest for the capital lease. The Short-Term Capital Lease Obligation is the portion of a Long-Term Capital Lease Obligation that is due over the next year.

Under US Generally Accepted Accounting Principles (GAAP), a capital lease is essentially equivalent to a purchase by the lessee if it meets the following criteria:

1. Ownership of the asset is transferred to the lessee at the end of the lease term;
2. The lease contains a bargain purchase option to buy the equipment at less than fair market value;
3. The lease term equals or exceeds 75% of the asset's estimated useful life;
4. The present value of the lease payments equals or exceeds 90% of the total original cost of the equipment.

Takeda Pharmaceutical Co Long-Term Capital Lease Obligation Related Terms

Thank you for viewing the detailed overview of Takeda Pharmaceutical Co's Long-Term Capital Lease Obligation provided by GuruFocus.com. Please click on the following links to see related term pages.

Takeda Pharmaceutical Co (Takeda Pharmaceutical Co) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Takeda Pharmaceutical Co Ltd (NYSE:TAK) » Definitions » Long-Term Capital Lease Obligation

Comparable Companies

Traded in Other Exchanges

TKPHF:USA TAK:Mexico 4502:Japan 4502:Japan 4502:Japan 4502:Japan TKDA:Germany TKD:Germany TKD:Germany TAKP34:Brazil

Address

1-1, Nihonbashi-Honcho 2-Chome, Chuo-ku, Tokyo, JPN, 103-8668

Website

https://www.takeda.com

Takeda Pharmaceutical is Japan's largest pharmaceutical company, with revenue of JPY 4 trillion in fiscal 2022. The company's five core therapeutic areas are oncology, gastroenterology, neuroscience, rare diseases, and plasma-derived therapies, which account for more than 80% of revenue. Its geographic footprint is well diversified, with 50% derived from the U.S., 20% from Japan, 20% from Europe and Canada.